Αρχική World News Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or... World News Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours Από Ogkologos - 25 Οκτωβρίου, 2024 1016 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CABINET study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... 9 Απριλίου, 2024 Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... 20 Οκτωβρίου, 2025 Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small... 25 Οκτωβρίου, 2026 Childhood cancer survivors at greater risk of ill health 22 Νοεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Black Patients Are More Likely to Die of Cancer—Here’s How One... Patient Guide in Testicular Cancer Now Available Also in Italian ESMO Welcomes European Parliament Resolution Marking World Cancer Day 7 Practical Tips for Taking Long-Term Medication